Understanding how tumor environments cause treatment resistance in glioblastoma
Defining Tumor Microenvironmental Interactions that drive THY1-Mediated Treatment Resistance in Glioblastoma
This study is looking at how the environment around glioblastoma tumors affects their resistance to treatment, with the goal of finding new therapies that can help patients get better.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11042243 on NIH RePORTER |
What this research studies
This research investigates the interactions within the tumor microenvironment that contribute to treatment resistance in glioblastoma, a type of brain cancer. By utilizing advanced modeling techniques and cancer genomics, the research aims to identify specific cellular interactions that hinder effective treatment. Patients may benefit from this research as it seeks to develop targeted therapies that can overcome these resistance mechanisms, potentially leading to improved outcomes. The research is led by Dr. Wajd Al-Holou at the University of Michigan, who is training under esteemed mentors in the field.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glioblastoma who are seeking innovative treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively target treatment-resistant glioblastoma.
How similar studies have performed: Previous research has shown promise in understanding tumor microenvironment interactions, suggesting that this approach could lead to significant advancements in glioblastoma treatment.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Al-Holou, Wajd — University of Michigan at Ann Arbor
- Study coordinator: Al-Holou, Wajd
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.